Resumen de Analisis de los factores pronosticos en el cancer de colon estadios ii y iii
ANÁLISIS DE LOS FACTORES PRONOSTICOS EN EL CANCER DE COLON ESTADIOS II Y III La tesis versa sobre un análisis retrospectivo, que incluye 213 paciente que padecieron cáncer de colon en estadio patológico II o III entre el año 2007 y 2010. Todos los sujetos fueron intervenidos de su neoplasia y posteriormente completaron tratamiento adyuvante con quimioterapia, dado que eran estadios III o estadios II con algún factor de mal pronóstico.
El objetivo primario de la tesis era determinar si alguno de los factores clinicos, histopatológicos y moleculares estudiados se verificaba como factor pronóstico independiente, a los 5 años de seguimientos, en términos de superviencia; supervivencia libre enfermedad [SLE], supervivencia global [SG] y/o supervivencia cáncer específica [SCE].
BIBLIOGRAFÍA (1) Sanchez MJ, Payer T, de Angelis R, et al. Cancer incidence and mortality in Spain, estimates and projections for the period 1981-2012. Ann Oncol 2010; 21 (Suppl, 3).
(2) Andre T, Boni C, Mounedji-Boudiaf L, et al. Multicenter International Study of Oxaliplati/5-FU/ Leucovorin in the Adjuvant treatment of colon cancer (MOSAIC) Investigators. Oxaliplatin, fluoracil, and leucovorin as adjuvant treatment for colon cancer. N Eng J Med. 2004; 350: 2343-51.
(3) Cassidy J, Scheithauer W, and McKendrick J, et al. Capecitabine (X) vs bolus 5FU/leucovorin (LV) as adjuvant therapy fror colon cancer (the X-ACT study): efficacy results of a phase III trial. J Clin Oncol.2004; 23:3509.
(4) Haller D, Tabernero J, Maroun J, et al. Firs efficacy findings from a randomized phase III trial of capecitabine + oxaliplatin vs bolus 5FU/LV for stage III colon cancer (N016968/XELOXA study). Eur J Cancer.2009; 7 (3): 4b (abst 5 LBA).
(5) Benson AB, Schrag D, Somerfield MR, et al. American society or clinical oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004; 22: 3408-19.
(6) Aust DE, Sommer U, Baretton BG. What can molecular pathology offer for optimal decision making? Annals of oncology 2012; 23: 63-70 (10).
(7) Chaves P, Cruz C, Lage P et al. Immunohistochemical detection of mismatch repair gene proteins as a useful tool for identification of colorectal carcinoma with the mutator phenotype. J Pathol 2000; 191: 355-60.
(8) Sargent DJ, Marsoni S, Monges G et al. Detective mismarch repair as a predictive marker for lack of efficacy or fluoracil-based adjuvant therapy in colon cancer. J Clin Oncol 2010; 7: 318-325.
(9) Isaksson-Mettävainio M, Palmqvist R, Dahlin AM, et al. High SMAD 4 levels appear in microsatellite instability and hypermethylated colon cancers, and indicate a better prognosis. International Journal of Cancer 2012; 131: 779-788.
(10) Ogino S, Meyerhardt JA, Irahara N, et al. KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALB 89803. Clin Cancer Res 2009; 15 (23): 7322-7329.
(11) Roth AD, Tejpar S, Delorenzi M, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial. Journal of clinical oncology 2010; 28 (3): 466-474.
(12) Fariña-Sarasqueta A, van Lijnschoten G, Moerland E, et al. The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage II colon cancer patients. Annals of oncology 2010.
(13) Zaanan A, Cuilliere-Dartigues P, Guilloux A, et al. Impact of p53 expression and microsatellite inestability on stage III colon cancer disease –free survival in patients treated by 5-fluoracil and leucovorin with or without oxaliplatin. Annals of oncology 2010; 21: 772-780.
(14) Manny D. Bacolod and Francis Barany. Molecular profiling of colon tumors: the search for clinically relevant biomarkers of progression, prognosis, therapeutics, and predisposition. Ann Surg Oncol 2011; 18: 3694
